Works by Sugiyama, Yosuke


Results: 39
    1
    2
    3
    4

    GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.

    Published in:
    Oncology, 2023, v. 101, n. 4, p. 224, doi. 10.1159/000529203
    By:
    • Sugiyama, Yosuke;
    • Naiki, Taku;
    • Tasaki, Yoshihiko;
    • Mimura, Yoshihisa;
    • Etani, Toshiki;
    • Noda, Yusuke;
    • Nozaki, Satoshi;
    • Shimizu, Nobuhiko;
    • Banno, Rika;
    • Nagai, Takashi;
    • Isobe, Teruki;
    • Ando, Ryosuke;
    • Moritoki, Yoshinobu;
    • Kataoka, Tomoya;
    • Odagiri, Kunihiro;
    • Aoki, Maria;
    • Gonda, Masakazu;
    • Yasui, Takahiro;
    • Hibi, Yoko
    Publication type:
    Article
    5
    6

    First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.

    Published in:
    Oncology, 2021, v. 99, n. 10, p. 622, doi. 10.1159/000517326
    By:
    • Naiki, Taku;
    • Nagai, Takashi;
    • Sugiyama, Yosuke;
    • Etani, Toshiki;
    • Nozaki, Satoshi;
    • Iida, Keitaro;
    • Noda, Yusuke;
    • Shimizu, Nobuhiko;
    • Isobe, Teruki;
    • Matsumoto, Daisuke;
    • Kubota, Hiroki;
    • Hamamoto, Shuzo;
    • Ando, Ryosuke;
    • Kawai, Noriyasu;
    • Yasui, Takahiro
    Publication type:
    Article
    7

    Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.

    Published in:
    Oncology, 2020, v. 98, n. 12, p. 876, doi. 10.1159/000508923
    By:
    • Etani, Toshiki;
    • Naiki, Taku;
    • Sugiyama, Yosuke;
    • Nagai, Takashi;
    • Iida, Keitaro;
    • Noda, Yusuke;
    • Shimizu, Nobuhiko;
    • Tasaki, Yoshihiko;
    • Mimura, Yoshihisa;
    • Okada, Tomoki;
    • Banno, Rika;
    • Kubota, Hiroki;
    • Hamamoto, Shuzo;
    • Ando, Ryosuke;
    • Kawai, Noriyasu;
    • Yasui, Takahiro
    Publication type:
    Article
    8
    9

    Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.

    Published in:
    Journal of Clinical Medicine, 2024, v. 13, n. 12, p. 3365, doi. 10.3390/jcm13123365
    By:
    • Hamamoto, Shuzo;
    • Tasaki, Yoshihiko;
    • Morikawa, Toshiharu;
    • Naiki, Taku;
    • Etani, Toshiki;
    • Taguchi, Kazumi;
    • Iwatsuki, Shoichiro;
    • Unno, Rei;
    • Takeda, Tomoki;
    • Nagai, Takashi;
    • Kawase, Kengo;
    • Mimura, Yoshihisa;
    • Sugiyama, Yosuke;
    • Okada, Atsushi;
    • Furukawa-Hibi, Yoko;
    • Yasui, Takahiro
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17

    Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.

    Published in:
    International Journal of Urology, 2023, v. 30, n. 10, p. 866, doi. 10.1111/iju.15220
    By:
    • Tasaki, Yoshihiko;
    • Hamamoto, Shuzo;
    • Sugiyama, Yosuke;
    • Tomiyama, Nami;
    • Naiki, Taku;
    • Etani, Toshiki;
    • Taguchi, Kazumi;
    • Matsuyama, Nayuka;
    • Sue, Yasuhito;
    • Mimura, Yoshihisa;
    • Kubota, Hiroki;
    • Noda, Yusuke;
    • Aoki, Maria;
    • Moritoki, Yoshinobu;
    • Nozaki, Satoshi;
    • Kurokawa, Satoshi;
    • Okada, Atsushi;
    • Kawai, Noriyasu;
    • Yasui, Takahiro;
    • Kimura, Kazunori
    Publication type:
    Article
    18

    Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.

    Published in:
    International Journal of Urology, 2023, v. 30, n. 9, p. 754, doi. 10.1111/iju.15198
    By:
    • Tomiyama, Nami;
    • Tasaki, Yoshihiko;
    • Hamamoto, Shuzo;
    • Sugiyama, Yosuke;
    • Naiki, Taku;
    • Etani, Toshiki;
    • Taguchi, Kazumi;
    • Matsuyama, Nayuka;
    • Sue, Yasuhito;
    • Mimura, Yoshihisa;
    • Odagiri, Kunihiro;
    • Noda, Yusuke;
    • Aoki, Maria;
    • Moritoki, Yoshinobu;
    • Nozaki, Satoshi;
    • Kurokawa, Satoshi;
    • Okada, Atsushi;
    • Kawai, Noriyasu;
    • Furukawa‐Hibi, Yoko;
    • Yasui, Takahiro
    Publication type:
    Article
    19

    Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance.

    Published in:
    Prostate Cancer (20903111), 2025, v. 2025, p. 1, doi. 10.1155/proc/8165686
    By:
    • Naiki, Taku;
    • Naiki-Ito, Aya;
    • Murakami, Akihiro;
    • Kato, Hiroyuki;
    • Sugiyama, Yosuke;
    • Kawai, Tatsuya;
    • Kato, Shinji;
    • Etani, Toshiki;
    • Nagai, Takashi;
    • Shimizu, Nobuhiko;
    • Morikawa, Toshiharu;
    • Aoki, Maria;
    • Gonda, Masakazu;
    • Kuang, Xiaochen;
    • Nagayasu, Yuko;
    • Hamamoto, Shuzo;
    • Yasui, Takahiro;
    • Takahashi, Satoru;
    • Bhattacharjee, Subrata
    Publication type:
    Article
    20
    21

    Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 24, p. 21666, doi. 10.1002/cam4.6724
    By:
    • Tasaki, Yoshihiko;
    • Sugiyama, Yosuke;
    • Hamamoto, Shuzo;
    • Naiki, Taku;
    • Uemura, Takehiro;
    • Yokota, Keisuke;
    • Kawakita, Daisuke;
    • Nakamura, Motoki;
    • Ogawa, Ryo;
    • Shimura, Takaya;
    • Mimura, Yoshihisa;
    • Hotta, Yuji;
    • Odagiri, Kunihiro;
    • Ito, Nanami;
    • Iida, Moeko;
    • Kimura, Yuka;
    • Komatsu, Hirokazu;
    • Kataoka, Hiromi;
    • Takiguchi, Shuji;
    • Morita, Akimichi
    Publication type:
    Article
    22

    Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.

    Published in:
    Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2024.1483956
    By:
    • Tasaki, Yoshihiko;
    • Hamamoto, Shuzo;
    • Yamashita, Shimpei;
    • Furukawa, Junya;
    • Fujita, Kazutoshi;
    • Tomida, Ryotaro;
    • Miyake, Makito;
    • Ito, Noriyuki;
    • Iwamoto, Hideto;
    • Mimura, Yoshihisa;
    • Sugiyama, Yosuke;
    • Unno, Rei;
    • Okada, Atsushi;
    • Yasui, Takahiro;
    • Furukawa-Hibi, Yoko
    Publication type:
    Article
    23
    24
    25
    26
    27

    Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 1, p. 165, doi. 10.1007/s10147-021-02046-z
    By:
    • Isobe, Teruki;
    • Naiki, Taku;
    • Sugiyama, Yosuke;
    • Naiki-Ito, Aya;
    • Nagai, Takashi;
    • Etani, Toshiki;
    • Nozaki, Satoshi;
    • Iida, Keitaro;
    • Noda, Yusuke;
    • Shimizu, Nobuhiko;
    • Tomiyama, Nami;
    • Banno, Rika;
    • Kubota, Hiroki;
    • Hamamoto, Shuzo;
    • Ando, Ryosuke;
    • Kawai, Noriyasu;
    • Yasui, Takahiro
    Publication type:
    Article
    28
    29

    C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.

    Published in:
    Cancers, 2024, v. 16, n. 9, p. 1725, doi. 10.3390/cancers16091725
    By:
    • Morikawa, Toshiharu;
    • Naiki, Taku;
    • Sugiyama, Yosuke;
    • Naiki-Ito, Aya;
    • Nagai, Takashi;
    • Etani, Toshiki;
    • Iida, Keitaro;
    • Isobe, Teruki;
    • Noda, Yusuke;
    • Shimizu, Nobuhiko;
    • Aoki, Maria;
    • Gonda, Masakazu;
    • Banno, Rika;
    • Kubota, Hiroki;
    • Ando, Ryosuke;
    • Umemoto, Yukihiro;
    • Kawai, Noriyasu;
    • Yasui, Takahiro
    Publication type:
    Article
    30
    31
    32

    Real‐world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.

    Published in:
    Asia Pacific Journal of Clinical Oncology, 2024, v. 20, n. 4, p. 515, doi. 10.1111/ajco.14073
    By:
    • Tasaki, Yoshihiko;
    • Ito, Nanami;
    • Mimura, Yoshihisa;
    • Sugiyama, Yosuke;
    • Ogawa, Ryo;
    • Shimura, Takaya;
    • Nakamura, Motoki;
    • Kawakita, Daisuke;
    • Hamamoto, Shuzo;
    • Uemura, Takehiro;
    • Yokota, Keisuke;
    • Iida, Moeko;
    • Odagiri, Kunihiro;
    • Kimura, Yuka;
    • Hotta, Yuji;
    • Komatsu, Hirokazu;
    • Okuda, Katsuhiro;
    • Niimi, Akio;
    • Yasui, Takahiro;
    • Iwasaki, Shinichi
    Publication type:
    Article
    33
    34
    35
    36

    Postoperative Bladder Neck to Pubic Symphysis Ratio Predictive for De Novo Overactive Bladder after Robot-Assisted Radical Prostatectomy.

    Published in:
    Diagnostics (2075-4418), 2023, v. 13, n. 20, p. 3173, doi. 10.3390/diagnostics13203173
    By:
    • Matsuyama, Nayuka;
    • Naiki, Taku;
    • Hamamoto, Shuzo;
    • Sugiyama, Yosuke;
    • Kubota, Yasue;
    • Hamakawa, Takashi;
    • Etani, Toshiki;
    • Iwatsuki, Shoichiro;
    • Taguchi, Kazumi;
    • Ota, Yuya;
    • Gonda, Masakazu;
    • Aoki, Maria;
    • Morikawa, Toshiharu;
    • Kato, Taiki;
    • Okada, Atsushi;
    • Yasui, Takahiro
    Publication type:
    Article
    37
    38
    39